✨ Onyx Summary Keros Therapeutics announced a strategic realignment to focus resources on its lead program, KER-065, and discontinue internal development of cibotercept following Phase 2 data in pulmonary arterial hypertension. The company also implemented board and leadership changes, including appointing Jean-Jacques Bienaimé as Chair and promoting Lorena Lerner, Ph.D.
✨ Onyx Summary Adverum Biotechnologies announced that CEO Laurent Fischer, M.D., and Board Member Szilárd Kiss, M.D., will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. The discussion will be webcast live, offering insights into Adverum’s intravitreal
✨ Onyx Summary Geron Corporation appointed Harout Semerjian as President and Chief Executive Officer, effective August 7, 2025, succeeding Interim CEO Dawn Carter Bir, who will remain on the Board of Directors. Semerjian, a 30-year hematology and oncology veteran with leadership roles at Novartis, Ipsen, and GlycoMimetics, joins Geron as it
✨ Onyx Summary Affinia Therapeutics has partnered with the DCM Foundation and the Genetic Cardiomyopathy Awareness Consortium to raise awareness of BAG3 dilated cardiomyopathy (DCM) and drive early genetic testing for this life-threatening heart disease. The collaboration underscores the growing role of precision medicine in cardiovascular care and highlights Affinia’s
